Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
ACS Infectious Diseases|October 10, 2017
Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanDPooja Gopal, Wilson Nartey, Priya Ragunathan, et al.
Bioorganic & Medicinal Chemistry|October 13, 2022
Structure activity relationship of pyrazinoic acid analogs as potential antimycobacterial agentsPooja V Hegde, Wassihun W Aragaw, Malcolm S Cole, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2021
A Leucyl-tRNA Synthetase Inhibitor with Broad-Spectrum Anti-Mycobacterial ActivityUday S Ganapathy, Rubén González Del Rio, Mónica Cacho-Izquierdo, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2023
Pharmacological validation of dihydrofolate reductase as a drug target in Mycobacterium abscessusWassihun Wedajo Aragaw, Dereje A Negatu, Christopher J Bungard, et al.
ACS Chemical Biology|May 13, 2021
Mycobacterium tuberculosis PanD Structure-Function Analysis and Identification of a Potent Pyrazinoic Acid-Derived Enzyme InhibitorPriya Ragunathan, Malcolm Cole, Chitra Latka, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 3, 2006
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosisUjjini H Manjunatha, Helena Boshoff, Cynthia S Dowd, et al.
ACS Medicinal Chemistry Letters|March 18, 2022
Structure-Activity Relationship of Anti-Mycobacterium abscessus Piperidine-4-carboxamides, a New Class of NBTI DNA Gyrase InhibitorsAndreas Beuchel, Dina Robaa, Dereje A Negatu, et al.
The Journal of Biological Chemistry|June 20, 2013
para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosisJun Zheng, Eric J Rubin, Pablo Bifani, et al.
Antimicrobial Agents and Chemotherapy|May 18, 2021
Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessusDereje Abate Negatu, Andreas Beuchel, Abdeldjalil Madani, et al.
Antimicrobial Agents and Chemotherapy|July 6, 2021
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessusUday S Ganapathy, Tian Lan, Philipp Krastel, et al.
Pageof 17